13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02011451December 201510/12/2013Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple SclerosisSafety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple SclerosisMultiple SclerosisDrug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator:Louisiana State University Health Sciences Center in New OrleansNational Multiple Sclerosis SocietyWithdrawn18 Years65 YearsBoth0Phase 2United States
2NCT01417312July 201115/8/2011Metabolic Effects of a Green Tea Extract in Multiple Sclerosis PatientsMultiple Sclerosis, Relapsing-RemittingDietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG);Dietary Supplement: PlaceboCharite University, Berlin, GermanyNULLCompleted20 Years60 YearsAll20N/AGermany
3NCT00799890May 200928/11/2008Sunphenon in Progressive Forms of Multiple SclerosisMonocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple SclerosisMultiple SclerosisDrug: Sunphenon EGCG;Drug: PlaceboFriedemann PaulTAIYO EUROPECompleted18 Years65 YearsAll61Phase 2/Phase 3Germany
4NCT00525668September 20074/9/2007Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Relapsing-remitting Multiple SclerosisDrug: epigallocatechin-gallate (Sunphenon);Drug: placeboCharite University, Berlin, GermanyNULLCompleted18 Years60 YearsAll120Phase 1/Phase 2Germany
5EUCTR2006-006323-39-DE19/06/200705/03/2007Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MSSunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS relapsing-remitting multiple sclerosisICD classification: G35.1Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg TM
Charité-Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
100Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2008-005213-22-DE22/08/2008SUPREMES - Sunphenon in progressive forms of multiple sclerosisSUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg
Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
60Phase 2;Phase 3Germany